Q32 Bio director granted 9,810 stock options

Q32 Bio Inc. director Isaac Manke received a grant of stock options covering 9,810 shares of common stock.

Rhea-AI Filing Summary

Q32 Bio Inc. director Isaac Manke received a grant of stock options covering 9,810 shares of common stock. These options have an exercise price of $12.64 per share and were awarded as compensation, not through an open-market purchase or sale.

The options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, subject to Manke’s continued board service on that vesting date. Following this grant, he holds 9,810 derivative securities tied to Q32 Bio common stock directly.

Insider Trade Summary

Grant/Award: 9,810 shares

Grant/Award 1 txn

Insider Manke Isaac

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,810	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,810 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options granted: 9,810 options Exercise price: $12.64 per share Shares underlying options: 9,810 shares +4 more

7 metrics

Options granted 9,810 options Stock Option (Right to Buy) grant to director

Exercise price $12.64 per share Exercise price for the granted stock options

Shares underlying options 9,810 shares Underlying Q32 Bio common stock for this award

Transaction code A (Grant, award, or other acquisition) Indicates compensation-related acquisition, not open-market trade

Vesting date Earlier of June 12, 2027 or next annual meeting Subject to continued board service at vesting

Expiration date June 11, 2036 Option expiration if not exercised earlier

Shares after transaction 9,810 derivative securities Total options held following this grant

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price of 12.6400 per underlying share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable in full"

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Q32 Bio (QTTB) director Isaac Manke report in this Form 4?

Isaac Manke reported receiving a grant of stock options for 9,810 shares of Q32 Bio common stock. The award is compensation-based, not an open-market trade, and reflects additional potential future equity exposure tied to the company’s share price.

How many Q32 Bio (QTTB) options did Isaac Manke receive and at what exercise price?

He received stock options covering 9,810 underlying shares of Q32 Bio common stock with an exercise price of $12.64 per share. These options only have value if the market price exceeds the exercise price after they vest and become exercisable.

When do Isaac Manke’s newly granted Q32 Bio (QTTB) options vest?

The options vest in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual stockholder meeting. Vesting is contingent on his continued service as a director through that applicable vesting date.

Is Isaac Manke’s Q32 Bio (QTTB) Form 4 a stock purchase or sale?

No, the Form 4 reports a grant of stock options as compensation, not a market purchase or sale of common shares. The transaction is coded “A” for grant or award, and no cash market trade is disclosed in this filing.

How many derivative securities does Isaac Manke hold after this Q32 Bio (QTTB) grant?

After the reported grant, Manke’s total reported derivative holdings from this award are 9,810 options tied to Q32 Bio common stock. These options are held directly and become exercisable only after the vesting conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manke Isaac

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		9,810		(1)	06/11/2036	Common Stock	9,810	$0	9,810	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)